Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 Published: May 2017 Single User PDF: US$ 3995 Order this report by calling or Send an to with your contact details and questions if 1 © ReportsnReports.com / Contact

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 The Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline report provides an overview of the genetic disorders pipeline landscape. It provides information on the therapeutics under development and key players involved in therapeutic development for Becker and Duchenne Muscular Dystrophy (BMD and DMD) and features dormant and discontinued projects. Both indications covered are inherited muscular dystrophies, a group of genetic, degenerative diseases primarily affecting voluntary muscles. BMD, the first type of muscular dystrophy, leads to symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls. There are a total of six products in development for this indication, by six separate companies. Access Complete Report at: cluster-muscular-dystrophy-drug-development-pipeline-review-2017.html. cluster-muscular-dystrophy-drug-development-pipeline-review-2017.html Offers from 10th May 2017 to 2nd June 2017 All reports priced >=1,000 – 20% Discount – Single User ; 25% Discount – Global Site License. Buy 2 Reports Get 1 Report Free Order this report by calling or Send an to with your contact details and questions if any. 2 © ReportsnReports.com / Contact

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 DMD is a condition which causes muscle weakness, and is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking. Key companies operating in this pipeline space include Sarepta Therapeutics, PTC Therapeutics, WAVE Life Sciences, Solid Biosciences, Summit Therapeutics and Catabasis Pharmaceuticals. Of particular importance are Sarepta, who are developing twelve distinct pipeline products for DMD. As with BMD, these are all smaller enterprises, although there is some involvement from larger pharmaceutical companies such as Pfizer and Merck in the DMD pipeline. There is a far larger pipeline for DMD than for BMD; there are a total of 108 products in development for DMD, by 57 companies and nine academic institutions. Inquire for Discount Order this report by calling or Send an to with your contact details and questions if any. 3© ReportsnReports.com / Contact

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 Key Companies Operating in this Pipeline include: The companies operating in this pipeline space are all small pharmaceutical enterprises, and consist of Armgo Pharma, Cardero Therapeutics, Milo Biotechnology, PTC Therapeutics, ReveraGen BioPharma and Sarepta Therapeutics. The majority of pipeline products for DMD target dystrophin which, as mentioned, is the causative gene for the disease. However, a number of products act on other molecular targets such as growth differentiation factor 8, nuclear factor kappa B and utrophin. The first two of these make up the pipeline for BMD, along with fork head box protein 1B. Buy a Copy of Order this report by calling or Send an to with your contact details and questions if any. 4© ReportsnReports.com / Contact

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 Scope of the Report Which companies are the most active within the pipeline for genetic disorder therapeutics? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in the field of genetic disorder therapeutics? Buy a Copy of Order this report by calling or Send an to with your contact details and questions if any. 5 © ReportsnReports.com / Contact

About ReportsnReports ReportsnReports.comReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Contact: Ritesh Tiwari Maharashtra, India. Tel: © ReportsnReports.com / Contact